The pre-market approval of PartoSure by the US Food and Drug Administration follows successful uptake of the rapid, accurate test in more than 35 countries across Europe, the Middle East, Asia and Latin America.
PartoSure, a non-invasive strip test that provides results in five minutes or less, has been shown in several published studies to have a higher positive predictive value for preterm birth compared to current diagnostic methods, while maintaining an equally high negative predictive value.
The test detects placental alpha microglobulin-1 (PAMG-1) in patients presenting with signs and symptoms of preterm labor.
Qiagen's comprehensive sexual and reproductive health portfolio includes PartoSure and the AmniSure ROM Test, an assay for rupture of membranes; differentiated core technologies; bioinformatics solutions for non-invasive prenatal testing; and the digene HC2 HPV test to screen for human papillomavirus and protect women from cervical cancer.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT